Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153672 · ClinicalTrials.gov registry record · NA
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
A NA study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT01153672 is a NA study of Stage IV Breast Cancer and Recurrent Breast Cancer that has completed, run by University of Washington. The registered enrollment target is 8 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01153672, a NA study of Stage IV Breast Cancer and Recurrent Breast Cancer, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- DRUG vorinostat
- PROCEDURE positron emission tomography
- RADIATION F-18 16 alpha-fluoroestradiol
Study Locations (1)
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-08-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153672
The ClinicalTrials.gov registry entry for NCT01153672 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (88% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01153672 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT01153672 about?
NCT01153672 is a clinical study titled "Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy". This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tu...
What is the current status of trial NCT01153672?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2010-11. Estimated completion is 2016-08-11.
What conditions does trial NCT01153672 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Cancer, Male Breast Cancer.
What interventions are being tested in trial NCT01153672?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), vorinostat (DRUG), positron emission tomography (PROCEDURE), F-18 16 alpha-fluoroestradiol (RADIATION).
Who is sponsoring clinical trial NCT01153672?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01153672 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Ask Questions (ASQ):Implementation of a Communication Intervention
COMPLETED · NA
-
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
COMPLETED · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.